Relative Value Partners Group’s Novo Nordisk NVO Stock Holding History

Relative Value Partners Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.31M	Buy	+16,151	New	+$2.14M	0.3%	80

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Relative Value Partners Group's NVO Position: Q2 2024 in Review

Relative Value Partners Group opened a new position in Novo Nordisk (NVO) in Q2 2024: 16,151 shares worth $2.31M. The stake represents 0.3% of the portfolio and ranks #80 among its holdings.

1,865 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

Relative Value Partners Group held 16,151 shares of Novo Nordisk worth $2.31M as of Q2 2024.
Novo Nordisk was a new Relative Value Partners Group position in Q2 2024.
Novo Nordisk made up 0.3% of Relative Value Partners Group's portfolio in Q2 2024, its #80 holding.
1,865 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.